JFL Life Sciences Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹0(0.00%)
Premium (ELP)
JFL Life Sciences Limited's achieved publicly listed status following its IPO debut on Sep 08, 2022 at the NSE platform. The offering successfully mobilized 29,78,000 Shares, with 29,78,000 Shares allocated to corporate growth initiatives.
Investment participation occurred within the established price band of ₹61 to ₹61, starting from minimum lots of 2000 shares. The subscription window from Aug 25, 2022 through Aug 30, 2022 enabled investor participation across market segments.
Share allocation was completed on Sep 06, 2022, determining ownership distribution among successful applicants. The listing represents a milestone achievement, transitioning the company to regulated public market status with associated responsibilities and opportunities.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
JFL Life Sciences Limited, established in 2010, is a pharmaceutical company specializing in the manufacturing of a variety of medicines. Its product range includes dry powder injections (B-Lactam), tablets, capsules (B-Lactam and general), and oral rehydration solutions (ORS). The company follows a bulk sales strategy, supplying its products to pharmaceutical marketers and traders who then distribute them to customers. JFL has a strong presence across India and exports to 10 countries worldwide. Internationally, JFL supplies products to African, Middle Eastern, and CIS countries through merchant exporters. The company is also registered with the Ministries of Health (MOH) in Kenya, Nigeria, Yemen, Cambodia, and Myanmar for specific products, with additional registrations in Ukraine, Uzbekistan, and Kazakhstan. JFL operates two leased manufacturing units in Gujarat to produce its pharmaceutical products.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
Product Registration: Approved by health authorities in multiple countries, ensuring global market access.
Experienced Leadership & Skilled Team: Led by industry experts with a dedicated workforce committed to excellence.
Quality Assurance: Strict quality control measures to maintain high standards in manufacturing.
Strong Brand & Reliability: Well-known for delivering trusted and effective pharmaceutical products.
NA
- Smiral Ashwinkumar Patel
- ejal Smiral Patel
JFL Life Sciences Limited
Kfin Technologies Limited